drugset / Trial / NCT04594642
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
NaSequentialOpen-labelTreatment
Summary
This phase 1 study will investigate the safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity of AZD0486, a CD19 x CD3 T-cell engaging bispecific antibody, in subjects with B-cell non-Hodgkin lymphoma (B-NHL).
Timeline
- Start
- 2021-03-02
- Primary completion
- 2028-06-19
- Completion
- 2028-06-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Surovatamig | Protein / enzyme biologic | — | Intravenous |